miR‑95 promotes osteosarcoma growth by targeting SCNN1A

Geng,Yannan; Zhao,Shaorong; Jia,Yutao; Xia,Gang; Li,Huiming; Fang,Zhao; Zhang,Quan; Tian,Rong

doi:10.3892/or.2020.7514

miR‑95 promotes osteosarcoma growth by targeting SCNN1A

Authors:
- Yannan Geng
- Shaorong Zhao
- Yutao Jia
- Gang Xia
- Huiming Li
- Zhao Fang
- Quan Zhang
- Rong Tian
View Affiliations

Affiliations: Department of Spinal Surgery, Tianjin Union Medical Center, Tianjin 300121, P.R. China, The 3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin 300060, P.R. China
Published online on: February 24, 2020 https://doi.org/10.3892/or.2020.7514
Pages: 1429-1436
Copyright: © Geng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is a common malignant bone tumor, presenting particularly in children and young adults, and accounts for approximately 19% of all malignant bone cancers. Despite advances in OS treatment, long‑term prognosis remains poor. miRNAs are non‑coding single‑stranded RNAs ~22 nucleotides in length. Increasing evidence suggests that numerous miRNAs may play critical roles in tumorigenesis and tumor progression; however, the role of miR‑95 in OS has not been examined. In the present study, we investigated the role of miR‑95 in OS using in vitro and in vivo models and publicly available expression data. Our findings indicate that abnormal miR‑95 expression occurs in OS, according to the Gene Expression Omnibus (GEO) database. The miR‑95 inhibitor reduced cell proliferation and promoted apoptosis in OS cell lines as detected by EdU staining, TUNEL staining and flow cytometry. Furthermore, a dual luciferase reporter assay revealed that miR‑95 regulates the cell cycle of OS cells and apoptosis by targeting sodium channel epithelial 1α subunit (SCNN1A). Additionally, miR‑95 antagomir suppressed the growth of U2OS xenograft tumors in a mouse model. In summary, our results suggest that miR‑95 induces OS growth in vitro and in vivo by targeting SCNN1A. Our results help clarify the mechanism underlying the miR‑95‑mediated effects on OS tumor growth, thus potentially establishing it as a diagnostic target.

View Figures

View References

1	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
2	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
3	Laux CJ, Berzaczy G, Weber M, Lang S, Dominkus M, Windhager R, Nöbauer-Huhmann IM and Funovics PT: Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome. Int Orthop. 39:97–104. 2015. View Article : Google Scholar : PubMed/NCBI
4	Bentwich L, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al: Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 37:766–70. 2005. View Article : Google Scholar : PubMed/NCBI
5	Prasad R and Katiyar SK: Down-regulation of miRNA-106b inhibits growth of melanoma cells by promoting G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein. Oncotarget. 5:10636–10649. 2014. View Article : Google Scholar : PubMed/NCBI
6	Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and Takahashi T: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
7	Lu C, Peng K, Guo H, Ren X, Hu S, Cai Y, Han Y, Ma L and Xu P: miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2. Oncol Lett. 16:3150–3156. 2018.PubMed/NCBI
8	Wu D, Zhang H, Ji F and Ding W: MicroRNA-17 promotes osteosarcoma cells proliferation and migration and inhibits apoptosis by regulating SASH1 expression. Pathol Res Pract. 215:115–120. 2019. View Article : Google Scholar : PubMed/NCBI
9	Rehei AL, Zhang L, Fu YX, Mu WB, Yang DS, Liu Y, Zhou SJ and Younusi A: MicroRNA-214 functions as an oncogene in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol Sci. 22:5156–5164. 2018.PubMed/NCBI
10	Wang X, Peng L, Gong X, Zhang X, Sun R and Du J: miR-423-5p inhibits osteosarcoma proliferation and invasion through directly targeting STMN1. Cell Physiol Biochem. 50:2249–2259. 2018. View Article : Google Scholar : PubMed/NCBI
11	Chen T, Li Y, Cao W and Liu Y: miR-491-5p inhibits osteosarcoma cell proliferation by targeting PKM2. Oncol Lett. 16:6472–6478. 2018.PubMed/NCBI
12	Wang WT, Qi Q, Zhao P, Li CY, Yin XY and Yan RB: miR-590-3p is a novel microRNA which suppresses osteosarcoma progression by targeting SOX9. Biomed Pharmacother. 107:1763–1769. 2018. View Article : Google Scholar : PubMed/NCBI
13	Ye J, Yao Y, Song Q, Li S, Hu Z, Yu Y, Hu C, Da X, Li H, Chen Q and Wang QK: Up-regulation of miR-95-3p in hepatocellular carcinoma promotes tumorigenesis by targeting p21 expression. Sci Rep. 6:340342016. View Article : Google Scholar : PubMed/NCBI
14	Zhang J, Zhang C, Hu L, He Y, Shi Z, Tang S and Chen Y: Abnormal expression of miR-21 and miR-95 in cancer stem-like cells is associated with radioresistance of lung cancer. Cancer Invest. 33:165–171. 2015. View Article : Google Scholar : PubMed/NCBI
15	Qin J, Teng JA, Zhu Z, Chen JX and Wu YY: Glargine promotes human colorectal cancer cell proliferation via upregulation of miR-95. Horm Metab Res. 47:861–865. 2015. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Allen-Rhoades W, Kurenbekova L, Satterfield L, Parikh N, Fuja D, Shuck RL, Rainusso N, Trucco M, Barkauskas DA, Jo E, et al: Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 4:977–988. 2015. View Article : Google Scholar : PubMed/NCBI
18	Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, et al: miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res. 73:6972–6986. 2013. View Article : Google Scholar : PubMed/NCBI
19	Qiu D, Han F and Zhuang H: MiR-499 rs3746444 polymorphism and hepatocellular carcinoma risk: A meta-analysis. J Cancer Res Ther. 14 (Suppl):S490–S493. 2018. View Article : Google Scholar : PubMed/NCBI
20	Kelly AD, Haibe-Kains B, Janeway KA, Hill KE, Howe E, Goldsmith J, Kurek K, Perez-Atayde AR, Francoeur N, Fan JB, et al: miRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 5:22013. View Article : Google Scholar : PubMed/NCBI
21	Heare T, Hensley MA and Dell'Orfano S: Bone tumors: Osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr. 21:365–372. 2009. View Article : Google Scholar : PubMed/NCBI
22	Braconi C, Henry JC, Kogure T, Schmittgen T and Patel T: The role of microRNAs in human liver cancers. Semin Oncol. 38:752–763. 2011. View Article : Google Scholar : PubMed/NCBI
23	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
24	Niu J, Sun Y, Guo Q, Niu D and Liu B: Serum miR-95-3p is a diagnostic and prognostic marker for osteosarcoma. Springerplus. 5:19472016. View Article : Google Scholar : PubMed/NCBI
25	Xi M, Cheng L, Hua W, Zhou YL, Gao QL, Yang JX and Qi SY: MicroRNA-95-3p promoted the development of prostatic cancer via regulating DKK3 and activating Wnt/β-catenin pathway. Eur Rev Med Pharmacol Sci. 23:1002–1011. 2019.PubMed/NCBI
26	Turashvili G, Lightbody ED, Tyryshkin K, SenGupta SK, Elliott BE, Madarnas Y, Ghaffari A, Day A and Nicol CJB: Novel prognostic and predictive microRNA targets for triple-negative breast cancer. FASEB J. May 29–2018.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
27	You H, Ge Y, Zhang J, Cao Y, Xing J, Su D, Huang Y, Li M, Qu S, Sun F and Liang X: Derlin-1 promotes ubiquitylation and degradation of the epithelial Na⁺ channel, ENaC. J Cell Sci. 130:1027–1036. 2017.PubMed/NCBI
28	Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A, et al: Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Res Treat. 146:287–297. 2014. View Article : Google Scholar : PubMed/NCBI
29	Qian Y, Wong CC, Xu J, Chen H, Zhang Y, Kang W, Wang H, Zhang L, Li W, Chu ESH, et al: Sodium channel subunit SCNN1AB suppresses gastric cancer growth and metastasis via GRP78 degradation. Cancer Res. 77:1968–1982. 2017. View Article : Google Scholar : PubMed/NCBI